Authors
Loading...
Essay explores risks of labeling gene-editing therapy as a cure for sickle cell disease, highlighting ethical concerns and communication gaps.
Wiggleton-Little et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: